• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Collaborating for Novel Solutions (CNS) Summit

November 7, 2021
November 10, 2021
7:00 am
10:00 pm
ET

The Collaborating for Novel Solutions Summit offers a one-of-a-kind experience that enables year-round conversations from pharma R&D leaders, innovators on the cutting edge of technology, and visionaries shaping the future of the clinical trial industry. The CNS Summit is the premiere community for R&D leaders to collaborate, learn from each other, and explore the future of drug development.

For these reasons and more, the CNS Summit was selected to be the official debut of Clario. We are proud to be an Executive Patron of CNS Summit, where we will have a spotlight session, 10×20 booth, and will be sending representatives from both legacy ERT and Bioclinica. This event will display our unity and collaboration while embodying what Clario now exemplifies.

Register now to see us there!

Get to know the new Clario, bringing the best of ERT and Bioclinica together, at CNS Summit.

Schedule a meeting with one of our many representatives at CNS for a one-on-one networking event. At Mystique from 3:30-5:00 pm Monday and Tuesday, November 8th and 9th.

Stop by the social lounge and relax and check your email and texts. Don’t worry. We have the wifi password!

Join speakers Philip Lake, Ph.D., Matthew Johnson, and Tairmae Kangarloo, from ERT and Takeda at @CNSSummit Spotlight Session: Tuesday, November 9, 1:00 pm, to learn how therapeutic area and domain expertise augments evidence-generating technologies and methodologies in Clinical Studies.

This CNS spotlight session will address

  • The impacts of decentralized and hybrid trials on clinical evidence generation
  • The influences of patient accountability
  • How science drives rich evidence
  • The impact of rich evidence on studies

Spotlight Summary

Ensuring rich evidence in a world that demands Trial Anywhere

With only 5-10% of clinical trials expected to be fully decentralized and 70-80% expected to be hybrid, sponsors, sites, and CROs need to continue to solve the challenges of generating rich evidence in this Trial Anywhere reality. While capturing high-quality data might meet regulatory standards, rich evidence determines the safety and efficacy of a medicine, medical device, or therapy. Generating rich, gold-standard evidence requires a fusion of scientific and technological excellence.

Please stop by the Clario Booth (#4) to familiarize yourself with our new look and feel, ask questions and find out how Clario can help you in transforming patients’ lives.